Transdermal Drug Delivery Systems Market by Type of Delivery System - Global Opportunity Analysis and Industry Forecast, 2017-2023

  • ID: 4333266
  • Report
  • Region: Global
  • 150 pages
  • Allied Analytics LLP
1 of 5

FEATURED COMPANIES

  • Acrux Limited
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Echo Therapeutics Inc.
  • Endo Pharmaceuticals Inc.
  • GlaxoSmithKline plc.
  • MORE
Transdermal route is a promising alternative for oral and injectable drug delivery wherein skin is the primary site for drug administration. This drug delivery system offers certain benefits, such as non-invasiveness, controlled & complete drug delivery from the dosage form and improved patient compliance. Transdermal patches, ointments, gel and implants are the popular transdermal drug delivery systems. Over the past few years, transdermal patches have gained significant importance. The transdermal drug delivery market has witnessed vertical growth over the past few decades and this trend is expected to continue during the forecast period. This growth would be driven by the steadily growing number of transdermal drug delivery products in the market resulting from the widespread adoption of these products by consumers. Johnson and Johnson, Acrux, Antares Pharma, Dermatrends Inc., Bayer HealthCare Pharmaceuticals, Novartis, Janssen Pharmaceuticals Inc. and Durect Corporation are some of the key leaders in the global transdermal drug delivery systems market. Recently, NuPathe Inc. received FDA clearance for their transdermal patch, Zeltrix. It is a single use preparation intended for the treatment of migraine pain.

The global transdermal drug delivery systems market is segmented on the basis of application, technology and geography. The application segment is further categorized into CNS, Pain Management, Hormone, Cardiovascular and Others. Transdermal patches for pain management and hormonal drug delivery dominate the market. Vivelle-dot and Climara are estrogen patches currently available in the market, offered by Novartis and Bayer HealthCare Pharmaceuticals, respectively. They are used in the delivery of estradiol for hormone replacement therapy. Based on technology, the global transdermal drug delivery systems market is segmented into Electroporation, Electric current, Lontophoresis, Radio Frequency, Microporation, Thermal, Mechanical arrays and Ultrasound. These technologies form an efficacious drug delivery system by improving the drug distribution pattern across the skin. Geographically, the global transdermal drug delivery systems market is segmented into North America, Europe, Asia-Pacific and LAMEA. North America and Europe dominate the global market due to extensive R&D efforts and presence of numerous approved transdermal products.

KEY BENEFITS

This report offers the following benefits in particular:

In-depth coverage of the global transdermal drug delivery systems market including drivers, restraints and opportunities would help professionals to better understand market behavior
Detailed study of the strategies of key leaders, partnerships and acquisitions in the global transdermal drug delivery systems market would be informative for professionals in the corporate sector
Porter’s Five Forces analysis examines the competitive structure of the global transdermal drug delivery systems market and would assist market strategists in making decisions.
Pin-point analysis of geographic segments helps to identify opportunities for growth within the global transdermal drug delivery systems market

KEY MARKET SEGMENTS

The global transdermal drug delivery systems market is segmented into three major categories: application, technology and geography.

MARKET BY APPLICATION

CNS
Pain Management
Hormone
Cardiovascular
Others
MARKET BY TECHNOLOGY

Electroporation
Electric current
Lontophoresis
Radio Frequency
Microporation
Thermal
Mechanical arrays
Ultrasound
MARKET BY GEOGRAPHY

North America
Europe
Asia-Pacific
LAMEA
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Acrux Limited
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Echo Therapeutics Inc.
  • Endo Pharmaceuticals Inc.
  • GlaxoSmithKline plc.
  • MORE
CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.1. KEY BENEFITS
1.2. KEY MARKET SEGMENTS
1.3. RESEARCH METHODOLOGY

1.3.1. Secondary research
1.3.2. Primary research
1.3.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.2.2.1. Competitive intelligence of companies and their strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. MARKET DYNAMICS

3.4.1. Drivers

3.4.1.1. Rising geriatric population
3.4.1.2. Increasing prevalence of chronic disorders
3.4.1.3. Rise in adoption of third-generation delivery systems

3.4.2. Restraints

3.4.2.1. Side-effects of the systems

3.4.3. Opportunities

3.4.3.1. Emerging nations

CHAPTER 4 TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY TYPE OF DELIVERY SYSTEM

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. PASSIVE DELIVERY SYSTEM

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.2.3.1. Matrix delivery system

4.2.3.1.1. Market size and forecast

4.2.3.2. Reservoir delivery system

4.2.3.2.1. Market size and forecast

4.3. ACTIVE DELIVERY SYSTEM

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.3.3.1. Structure-based drug delivery system

4.3.3.1.1. Market size and forecast

4.3.3.2. Electrically-based drug delivery system

4.3.3.2.1. Market size and forecast
4.3.3.2.2. Iontophoresis

4.3.3.2.2.1. Market size and forecast

4.3.3.2.3. Electroporation

4.3.3.2.3.1. Market size and forecast

4.3.3.2.4. Sonophoresis

4.3.3.2.4.1. Market size and forecast

4.3.3.3. Other

4.3.3.3.1. Market size and forecast

CHAPTER 5 TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY APPLICATION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. ANALGESICS

5.2.1. Market size and forecast

5.3. HORMONE REPLACEMENT THERAPY

5.3.1. Market size and forecast

5.4. HYPERTENSION

5.4.1. Market size and forecast

5.5. MOTION SICKNESS

5.5.1. Market size and forecast

5.6. SMOKING CESSATION

5.6.1. Market size and forecast

5.7. OTHERS

5.7.1. Market size and forecast

CHAPTER 6 TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY REGION

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Growth factors and opportunities
6.2.3. Market size and forecast

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Growth factors and opportunities
6.3.3. Market size and forecast

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Growth factors and opportunities
6.4.3. Market size and forecast

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Growth factors and opportunities
6.5.3. Market size and forecast

CHAPTER 7 COMPANY PROFILES

7.1. ACRUX LIMITED

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Business performance
7.1.5. Key strategic moves and developments
7.1.6. Strategy share (%)

7.2. BAYER AG

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Business performance
7.2.5. Key strategic moves and developments
7.2.6. Strategy share (%)

7.3. BOEHRINGER INGELHEIM GMBH

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Business performance
7.3.5. Key strategic moves and developments
7.3.6. Strategy share (%)

7.4. BRISTOL-MYERS SQUIBB COMPANY

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Business performance
7.4.5. Key strategic moves and developments
7.4.6. Strategy share (%)

7.5. ECHO THERAPEUTICS, INC.

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Business performance
7.5.5. Key strategic moves and developments
7.5.6. Strategy share (%)

7.6. ENDO PHARMACEUTICALS INC.

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Business performance
7.6.5. Key strategic moves and developments
7.6.6. Strategy share (%)

7.7. GLAXOSMITHKLINE PLC

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Business performance
7.7.5. Key strategic moves and developments
7.7.6. Strategy share (%)

7.8. JOHNSON & JOHNSON

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Business performance
7.8.5. Key strategic moves and developments
7.8.6. Strategy share (%)

7.9. MYLAN N.V.

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Business performance
7.9.5. Key strategic moves and developments
7.9.6. Strategy share (%)

7.10. NOVARTIS AG

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Business performance
7.10.5. Key strategic moves and developments
7.10.6. Strategy share (%)
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Acrux Limited
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Echo Therapeutics Inc.
  • Endo Pharmaceuticals Inc.
  • GlaxoSmithKline plc.
  • MORE
According to a new report titled, "Transdermal Drug Delivery Systems Market by Type of Delivery System and Application: Global Opportunity Analysis and Industry Forecast, 2017-2023," the global transdermal drug delivery systems market was valued at $ 32,516 million in 2016, and is projected to reach $61,689 million by 2023, growing at a CAGR of 9.5% from 2017 to 2023. The passive system segment held more than three-fifths share of the total market in 2016.

Transdermal drug delivery systems are used to deliver drug through intact skin at a controlled rate into the systemic circulation. Increase in geriatric population and rise in number of patients suffering from chronic disorders, such as hypertension, diabetes, and angina, are expected to drive the market growth. Moreover, surge in adoption of new delivery system technologies, such as ultrasound, boosts the market growth. However, disadvantages of these delivery systems, such as irritation at the site of application and edema, are expected to impede the market growth.

The passive system segment is expected to dominate the market throughout the analysis period, owing to increase in the incidence of chronic disorders, such as hypertension. The active system segment is expected to register highest CAGR of 12.8% during the forecast period.

Key Findings of the Transdermal Drug Delivery Systems Market:

Reservoir system segment is projected to grow at a CAGR of 7.3% during the forecast period.
Matrix system contributed for nearly two-third share of the global passive transdermal drug delivery systems market, in 2016.
Structure-based drug delivery system segment is expected to register the highest CAGR of 13.3% during the analysis period.
Cardiovascular disorders segment is expected to grow at the highest CAGR of 10.8% during the forecast period.
France and Germany collectively contributed for more than one-third share of the European transdermal drug delivery systems market in 2016.
Japan is the major shareholder, accounting for more than one-third share of the Asia-Pacific transdermal drug delivery systems market in 2016.
Asia-Pacific is projected to register the highest CAGR of 10.1% during the forecast period, owing to improvement in healthcare infrastructures and rise in expenditures in emerging markets (India and China) to cater to the unmet medical needs. Technological advancements to develop cost-effective technologies in these nations offer a lucrative opportunity for the market growth.

The major companies profiled in the report includes Novartis AG, Johnson & Johnson, Mylan N.V., Boehringer Ingelheim GmbH, Bayer AG, Bristol-Myers Squibb Company, GlaxoSmithKline plc., Acrux Limited, Echo Therapeutics, Inc., and Endo Pharmaceuticals Inc.
Note: Product cover images may vary from those shown
5 of 5
  • Novartis AG
  • Johnson & Johnson
  • Mylan N.V.
  • Boehringer Ingelheim GmbH
  • Bayer AG
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline plc.
  • Acrux Limited
  • Echo Therapeutics Inc.
  • Endo Pharmaceuticals Inc.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll